Skip to main content
Top

Journal of Endocrinological Investigation

Issue 5/1997

Content (13 Articles)

Developmental patterns of serum 3α-androstanediol glucuronide

H. L. Rittner, P. D. K. Lee, W. F. Blum, H. G. Doerr, J. Steiss, J. Kreuder, W. Rascher, W. Kiess

The statistical analysis of neonatal TSH results from congenital hypothyroidism screening programs provides a useful tool for the characterization of moderate iodine deficiency regions

G. Costante, L. Grasso, O. Ludovico, M. F. Marasco, M. Nocera, E. Schifino, L. Rivalta, C. Capula, R. Chiarella, S. Filetti, G. Parlato

Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa

M. Giusti, L. Foppiani, P. Ponzani, C. M. Cuttica, M. R. Falivene, S. Valenti

Cushing’s syndrome due to ACTH-independent bilateral adrenocortical macronodular hyperplasia

M. Terzolo, A. Boccuzzi, A. Alí, E. Bollito, C. De Risi, P. Paccotti, A. Angeli

Case Report

Pulmonary lymphangioleiomyoma in a patient with multiple endocrine neoplasia Type I

V. Carnevale, E. Romagnoli, D. Remotti, E. D’Erasmo, G. Spagna, D. Pisani, R. Rosso, S. Minisola, G. F. Mazzuoli

Case Report

Appearance of Graves’ disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma

F. Monzani, P. Del Guerra, N. Caraccio, A. Casolaro, P. V. Lippolis, O. Goletti

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine